title: Baseline characteristics and prevalence of HPV 6, 11, 16, 18 in young German women participating in phase III clinical trials of a quadrivalent HPV (6/11/16/18) vaccine.
abstract: BACKGROUND
  As limited data among German women exist about HPV, Chlamydia trachomatis (CT) and Neisseria gonorrhoeae, we report the prevalence of these genital infections and general baseline demographics of the young German women enrolled in the phase III trials of the quadrivalent HPV vaccine.
  
  
  METHODS
  German females (n = 437; 9-23 years) were recruited among 3 international phase 3 studies of an HPV-6/11/16/18 vaccine. We present baseline characteristics, prevalence of HPV-6/11/16/18 and, for women aged 16-23, abnormal cervical cytology and sexually transmitted diseases.
  
  
  RESULTS
  Chlamydia trachomatis and Neisseria gonorrhoeae prevalence was 5 and 0.3%, respectively. Approximately 17% of participants had HPV-6, 11, 16, or 18 DNA or antibodies. All subjects <17 years were naïve to the four vaccine types.
  
  
  CONCLUSIONS
  The results of the vaccine trials have demonstrated that it is worth administering prophylactic HPV vaccines before sexual debut; however, none of these sexually active German women were positive to all four types and most were positive to only one type. Thus, all women had the potential to benefit from vaccination with a quadrivalent HPV vaccine.
authors.affiliation: First Department of Obstetrics and Gynaecology - Klinikum Innenstadt, Ludwig-Maximilian-University Munich, Germany.
authors.forename: Elisabeth
authors.initials: E
authors.lastname: Barthell
authors.forename: Linn
authors.initials: L
authors.lastname: Woelber
authors.forename: Karin
authors.initials: K
authors.lastname: Hellner
authors.forename: Birka
authors.initials: B
authors.lastname: Camerer
authors.forename: Friederike
authors.initials: F
authors.lastname: Gieseking
authors.forename: Maik
authors.initials: M
authors.lastname: Hauschild
authors.forename: Ioannis
authors.initials: I
authors.lastname: Mylonas
authors.forename: Klaus
authors.initials: K
authors.lastname: Friese
authors.forename: Heather L
authors.initials: HL
authors.lastname: Sings
authors.forename: Radha
authors.initials: R
authors.lastname: Railkar
authors.forename: Christine
authors.initials: C
authors.lastname: Gause
authors.forename: Eliav
authors.initials: E
authors.lastname: Barr
mesh_terms: D000293:Adolescent; D052685:Alphapapillomavirus / Q000302:isolation & purification*; D002690:Chlamydia Infections / Q000453:epidemiology*; D017326:Clinical Trials, Phase III as Topic; D005260:Female; D005858:Germany / Q000453:epidemiology; D006069:Gonorrhea / Q000453:epidemiology*; D000068857:Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18; D006801:Humans; D030361:Papillomavirus Infections / Q000453:epidemiology*; D053918:Papillomavirus Vaccines; D015995:Prevalence; D016032:Randomized Controlled Trials as Topic; D055815:Young Adult
chemical_list: D000068857:Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18; D053918:Papillomavirus Vaccines